Novo Nordisk Raises Forecasts on New Obesity Drug

Описание: Aug.05 -- Lars Fruergaard Jorgensen, Novo Nordisk chief executive officer, discusses first half earnings results. The Danish drug-maker raised its profit and sales forecasts for the year, reflecting high demand for its new obesity medication. He speaks with Bloomberg's Dani Burger on "Bloomberg Surveillance: Early Edition".